Citizens JMP analyst Jonathan Wolleben downgraded Rallybio (RLYB) to Market Perform from Outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Rallybio discontinues RLYB212 program
- Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
- Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
- Rallybio Corporation Reports 2024 Financial Results and Progress
- Promising Developments and Financial Stability Support Buy Rating for Rallybio